KLAR fundamentals
Key facts
Market capitalization—
Founded—
CEO—
Website—
About
Klaria Pharma Holding AB engages in the development and commercialization of pharmaceutical products for migraine and cancer-related pain. Its operation is based on a patented drug delivery platform in an alginate-based polymer film. The firm's project portfolio currently includes various pain states, opioid overdoses, cannabinoids, and allergic shock. The company was founded by Scott Boyer and Fredrik Hübinette in 2015 and is headquartered in Uppsala, Sweden.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
Dividends
Dividend yield, history and sustainability
No dividends
KLAR has never paid dividends and has no current plans to do so.
Financial health
Financial position and solvency of the company